

## NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

### Proposed Single Technology Appraisal (STA)

#### Methylalntrexone bromide for treating opioid induced constipation [ID700]

#### Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> <li>• TMC Pharma Services (methylalntrexone)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• Action on Pain</li> <li>• Afiya Trust</li> <li>• Black Health Agency</li> <li>• Bladder and Bowel Foundation</li> <li>• Cancer Black Care</li> <li>• Cancer Equality</li> <li>• Equalities National Council</li> <li>• Helen Rollason Cancer Charity</li> <li>• IBS Network</li> <li>• Independent Cancer Patients Voice</li> <li>• Macmillan Cancer Support</li> <li>• Maggie's Centres</li> <li>• Marie Curie Cancer Care</li> <li>• Muslim Council of Britain</li> <li>• Muslim Health Network</li> <li>• Pain Concern</li> <li>• Pain Relief Foundation</li> <li>• Pain UK</li> <li>• Promocon</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> </ul> <p><u>Professional groups</u></p> <ul style="list-style-type: none"> <li>• Association of Cancer Physicians</li> <li>• Association of Coloproctology of Great Britain and Ireland</li> <li>• Association for Continence Advice</li> <li>• Association for Palliative Medicine</li> <li>• British Geriatrics Society</li> <li>• British Pain Society</li> <li>• British Psychosocial Oncology Society</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• Allied Health Professionals Federation</li> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Care Quality Commission</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Healthcare Improvement Scotland</li> <li>• Medicines and Healthcare products Regulatory Agency</li> <li>• National Association of Primary Care</li> <li>• National Pharmacy Association</li> <li>• NHS Alliance</li> <li>• NHS Commercial Medicines Unit</li> <li>• NHS Confederation</li> <li>• Scottish Medicines Consortium</li> </ul> <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> <li>• AstraZeneca (naloxegol )</li> <li>• Abbott Laboratories UK (lactulose)</li> <li>• Actavis UK (glycerol suppositories, bisacodyl, senna)</li> <li>• Amdipharm Mercury Company (methylcellulose)</li> <li>• Boehringer Ingelheim (bisacodyl, docusate, macrogol, sodium picosulphate)</li> <li>• B R Pharma (senna laxative)</li> <li>• Cardinal Health Martindale Products (glycerol suppositories)</li> <li>• Laboratorios Casen Fleet (sodium dihydrogen phosphate dehydrate, disodium hydrogen phosphate dodecahydrate enema)</li> <li>• Chanelle Medical (bisacodyl, senna,</li> </ul>

National Institute for Health and Care Excellence

Provisional matrix for the proposed technology appraisal of methylalntrexone bromide for treating opioid induced constipation [ID700]

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> <li>• British Society of Gastroenterology</li> <li>• Cancer Research UK</li> <li>• Primary Care Society for Gastroenterology</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> <li>• Royal Pharmaceutical Society</li> <li>• Royal Society of Medicine</li> <li>• UK Health Forum</li> <li>• UK Clinical Pharmacy Association</li> <li>• UK Oncology Nursing Society</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health</li> <li>• NHS England</li> <li>• NHS Bath and North East Somerset CCG</li> <li>• NHS Wiltshire CCG</li> <li>• Welsh Government</li> </ul>	<p>macrogol)</p> <ul style="list-style-type: none"> <li>• Chatfield Pharmaceuticals (bisacodyl)</li> <li>• Chemidex Pharma (phosphate enema, arachis oil enema)</li> <li>• Dr. Reddy's Laboratories UK (bisacodyl)</li> <li>• Hermal (ispaghula husk, glycerol suppositories, senna)</li> <li>• Intrapharm Laboratories (lactulose)</li> <li>• Medreich (bisacodyl)</li> <li>• Meda Pharmaceuticals (macrogol)</li> <li>• Napp Pharmaceuticals Limited (naloxone-oxycodone)</li> <li>• Novartis Consumer Health (lactulose, senna)</li> <li>• Norgine Pharmaceuticals (sterculia/frangula, macrogol, docusate sodium enema)</li> <li>• Orbis Consumer Products (glycerol suppositories)</li> <li>• Pinewood Healthcare (sodium citrate enema)</li> <li>• Resolution Chemicals (lactulose)</li> <li>• Teva UK (lactulose)</li> <li>• The Boots Company (senna)</li> <li>• Thornton &amp; Ross (macrogol, magnesium hydroxide, glycerol suppositories, senna)</li> <li>• UCB Pharma (sodium citrate enema, docusate)</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• Cochrane Inflammatory Bowel Disease and Functional Bowel Disorders Group</li> <li>• CORE (Digestive Disorders Foundation)</li> <li>• Institute of Cancer Research</li> <li>• MRC Clinical Trials Unit</li> <li>• National Cancer Research Institute</li> <li>• National Cancer Research Network</li> <li>• National Institute for Health Research</li> </ul> <p><u>Evidence Review Group</u></p> <ul style="list-style-type: none"> <li>• Evidence Review Group tbc</li> <li>• National Institute for Health Research Health Technology Assessment</li> </ul>

National Institute for Health and Care Excellence

Provisional matrix for the proposed technology appraisal of methylnaltrexone bromide for treating opioid induced constipation [ID700]

Consultees	Commentators (no right to submit or appeal)
	<p data-bbox="858 306 1026 340">Programme</p> <p data-bbox="818 376 1230 409"><u>Associated Guideline groups</u></p> <ul data-bbox="810 416 1358 524" style="list-style-type: none"> <li data-bbox="810 416 1358 450">• National Clinical Guidelines Centre</li> <li data-bbox="810 456 1358 524">• National Collaborating Centre for Cancer</li> </ul> <p data-bbox="818 566 1286 600"><u>Associated Public Health groups</u></p> <ul data-bbox="810 607 1174 678" style="list-style-type: none"> <li data-bbox="810 607 1174 640">• Public Health England</li> <li data-bbox="810 647 1174 678">• Public Health Wales</li> </ul>

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

***PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS***

### Definitions:

#### Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-company consultees are invited to submit a statement<sup>1</sup>, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

#### Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that markets comparator technologies;

Healthcare Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the *British National Formulary*).

All non-company commentators are invited to nominate clinical specialists or patient experts.

#### Evidence Review Group (ERG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the company evidence submission to the Institute.

---

<sup>1</sup>Non-company consultees are invited to submit statements relevant to the group they are representing.